Dear Colleagues,

According to the WHO, noncommunicable diseases (NCDs) continue to represent 7 of the 10 leading causes of death globally, with an impact on 74% of all deaths worldwide, represented by 41 million people each year. The major NCDs are cardiovascular diseases (heart attacks and strokes), cancers, chronic respiratory diseases (chronic obstructive pulmonary disease and asthma), and diabetes. Cardiovascular diseases account for the highest mortality from NCDs, with 17.9 million deaths each year, followed by cancers with 9.3 million deaths, chronic respiratory diseases with 4.1 million deaths, and diabetes with 2.0 million deaths (including deaths from kidney disease caused by diabetes). The medical and surgical approach to NCDs continuously requires novel polymeric biomaterials for tissue engineering and regenerative medicine to provide timely and adequate interventions that reduce the level of deaths and, moreover, maintain an adequate quality of life for recovering patients. Biomaterials offer architectural frameworks that simulate the native extracellular matrix to encourage cell growth, tissue repair, and regeneration. Therefore, novel biopolymers are sought to fulfill adequate mechanical and biological functions. Tissue engineering is dedicated to assembling functional constructs that restore or maintain damaged tissues, and regenerative medicine is focused on developing and applying new treatments to regrow, repair, or replace damaged or diseased cells, organs, or tissues.

This Special Issue aims to consider research on novel polymeric biomaterials and their potential application in restoring or replacing cells, organs, or tissues.

We invite authors to contribute original research articles or review articles covering different topics of interest in novel polymeric biomaterials for tissue engineering and regenerative medicine, such as (i) different routes for obtaining new polymers for tissue engineering; (ii) characterization of new biomaterials; (iii) nanotechnology for drug delivery and gene therapy; (iv) films with multifunctional properties; (v) membranes as scaffolds; (vi) injectable, thermosensitive, self-healing hydrogels; (vii) microparticles for the transport of biological components; (viii) nanotechnology for drug delivery and gene therapy; (ix) biomechanical characterization of biomaterials; (x) simulation of the interaction of biomaterials with biological components; (xi) natural products, such as new biomaterials; (xii) preclinical and clinical trials; (xiii) pharmacoeconomics of biomaterials in tissue engineering and regenerative medicine; and (xiv) case studies of commercial biomaterials.

Dr. Gerardo Leyva-Gómez
Dr. María Luisa Del Prado-Audelo
Dr. Hernán Cortés
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• cancer targeting
• diabetes
• cardiovascular diseases
• chronic respiratory diseases
• CNS targeting
• biomolecule-based hydrogels
• plant extract
• phytotherapy
• anti-inflammatory activity
• cell signaling
• biopharmaceutics
• supramolecular self-assembly
• drug delivery systems
• biomaterials and polymer chemistry
• novel drug delivery designs
• biomedical applications
• nanomedicine
• tissue engineering
• regenerative medicine